Warner-lambert Company

Vijaykumar M Baragi

David T Connor

Diane H Boschelli

Richard Raymond Renkiewicz

Joseph Edwin Low

Linda Lea Johnson

Madhav Narasimha Devalaraja

Donald John Hupe

Qi-Zhuang Ye

Howard Glenn Welgus

Vaishalee A Padgaonkar

The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.

Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor

A process for the production of the catalytic domain, without propeptide, of a matrix metalloproteinase is described which comprises culturing transformed host cells carrying a DNA sequence encoding the catalytic domain as well as a method for screening for inhibitors of a matrix metalloproteinase; a method for determining the 3-dimensional structure of the catalytic domain of a matrix metalloproteinase; and pharmaceutical compositions of human stromelysin catalytic domain protein which are useful in treating herniated vertebral discs, dermal ulcers, modifying scar tissue formation, and joint diseases.

Process for the production of stromelysin catalytic domain protein

The present invention provides a method of inhibiting connective tissue degradation that comprises administering to a patient having a condition in which connective tissue is degraded a therapeutically effective amount of a compound having the formula

Method of inhibiting connective tissue degradation

The manufacture and use of compounds of the formula ##STR1## wherein Y is O or S, R.sub.1 is hydrogen or alkyl, and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are hydrogen or various substituent groups, and pharmaceutically acceptable acid addition salts thereof. The compounds have activity as inhibitors of the IL-I or other agonist-induced proteoglycan degradation in bovine nasal cartilage and pharmaceutical compositions containing such compounds are described to treat conditions advantageously affected by such inhibition including arthritis.

Benzylidene-lactone derivatives of fenamates and their thiocarbonyl

Benzylidene-lactone and their thiocarbonyl analogs as inhibitors of

Growing community of inventors

Ann Arbor, MI, United States of America

Vijaykumar M Baragi